Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients expected in Q3 2024.

2. Phase 2 data of BDTX-1535 in 1L non-classical EGFRm NSCLC patients anticipated in Q1 2025.

3. Initial Phase 1 data of BDTX-4933 in KRASm NSCLC expected in Q4 2024.

4. Cash position of $123.0 million as of June 30, 2024, expected to fund operations into Q4 2025.

5. Q2 2024 net loss of $19.9 million, compared to $19.2 million in Q2 2023.

6. R&D expenses decreased to $12.6 million, while G&A expenses increased to $9.6 million in Q2 2024.

Positive

• Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024
• Phase 2 data of BDTX-1535 in 1L non-classical EGFRm NSCLC patients expected in Q1 2025
• Initial Phase 1 data of BDTX-4933 in KRASm NSCLC anticipated in Q4 2024
• Cash position of $123.0 million expected to fund operations into Q4 2025
• R&D expenses decreased from $13.2 million in Q2 2023 to $12.6 million in Q2 2024

Negative

• Net loss increased from $19.2 million in Q2 2023 to $19.9 million in Q2 2024
• G&A expenses increased from $6.9 million in Q2 2023 to $9.6 million in Q2 2024

Financial Analyst

Black Diamond Therapeutics' Q2 2024 results reveal a stable financial position with $123.0 million in cash and investments, expected to fund operations into Q4 2025. The net loss increased slightly to $19.9 million from $19.2 million year-over-year. R&D expenses decreased due to efficiency measures, while G&A expenses rose due to increased professional fees.

The company's cash burn rate remains relatively consistent, with $14.7 million used in operations this quarter compared to $14.4 million in Q2 2023. This burn rate suggests careful financial management, but investors should monitor how long the current cash reserves can sustain operations, especially as clinical trials progress.

While the financial position appears stable, the lack of revenue and increasing net losses highlight the importance of successful clinical trial outcomes for the company's future prospects.

Oncology Research Analyst

Black Diamond's pipeline progress is promising, with BDTX-1535 showing potential in addressing a broader range of EGFR mutations in NSCLC. The revelation that 20-30% of newly diagnosed EGFRm NSCLC patients have non-classical mutations underscores the market opportunity.

The upcoming Phase 2 data for BDTX-1535 in Q3 2024 and Q1 2025 are critical milestones. Positive results could position the drug as a significant player in the EGFRm NSCLC space, especially for patients with non-classical mutations or acquired resistance.

The brain-penetrant properties of BDTX-1535 demonstrated in the GBM trials are noteworthy, potentially expanding its application to brain metastases. Additionally, the progress of BDTX-4933 targeting KRAS, NRAS and BRAF mutations broadens the company's oncology portfolio, with data expected in Q4 2024.

These developments indicate a robust pipeline, but success hinges on forthcoming clinical data.

Market Research Analyst

The upcoming presentation at the 2024 ESMO Congress on real-world evidence for non-classical EGFR mutations in NSCLC is significant. It could validate the unmet medical need that Black Diamond is targeting with BDTX-1535, potentially strengthening the drug's market position.

The company's focus on underserved mutation profiles in NSCLC, particularly non-classical EGFR mutations and the C797S resistance mutation, could carve out a niche in a competitive market. The potential to address 20-30% of newly diagnosed EGFRm NSCLC patients with non-classical mutations represents a substantial market opportunity.

However, the success of BDTX-1535 and BDTX-4933 will depend on their efficacy compared to existing therapies and emerging competitors. Investors should closely monitor the upcoming clinical data releases, as these will be important in determining the drugs' commercial viability and Black Diamond's future market position in targeted oncology therapeutics.

• Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024
  
• On track to announce initial Phase 2 data of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC in Q1 2025, and initial Phase 1 data of BDTX-4933 in KRASm NSCLC in Q4 2024
• Upcoming poster presentation at 2024 ESMO Congress in September, titled “Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients with Non-classical EGFR Mutations Demonstrates High Unmet Medical Need”
• Cash, cash equivalents, and investments of $123.0 million as of June 30, 2024, expected to be sufficient to fund operations into Q4 of 2025

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.

“We continue to execute on enrollment of patients with EGFR mutant NSCLC into second/third-line and first-line Phase 2 cohorts, and remain on track to announce initial results later in the third quarter of this year and in the first quarter of 2025, respectively”, said Mark Velleca, M.D., Ph.D., Chief Executive Officer of Black Diamond Therapeutics. “We also look forward to sharing analyses of real world data at the 2024 ESMO Congress in September 2024 on treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations that demonstrate a significant unmet medical need.”

Recent Developments & Upcoming Milestones:

BDTX-1535:

• In April 2024, Black Diamond described real world evidence of the evolving EGFR mutation landscape in patients with non-small cell lung cancer (NSCLC) and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies at the 2024 American Association for Cancer Research (AACR) annual meeting. The analyses revealed a spectrum of previously underappreciated non-classical mutations, as well as an increased prevalence of the acquired resistance mutation C797S. These non-classical EGFR mutations were present in 20-30% of newly diagnosed epidermal growth factor receptor mutation positive (EGFRm) NSCLC patients.
• In June 2024, Black Diamond presented additional data from the Phase 1 dose escalation trial of BDTX-1535 in patients with relapsed/recurrent glioblastoma (GBM), and initial intratumoral pharmacokinetic data from a “window of opportunity” (also known as a Phase 0/1 “Trigger”) trial sponsored by the Ivy Brain Tumor Center, in patients with recurrent high-grade glioma (HGG), at the American Society of Clinical Oncology (ASCO) Annual Meeting. Safety and tolerability data in the Phase 1 trial were consistent with BDTX-1535 clinical data in patients with NSCLC previously presented in October 2023 at the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics. Among 19 efficacy evaluable patients, several experienced stable disease with promising durability. Results from the investigator-sponsored trial demonstrated that BDTX-1535 penetrates the blood brain barrier with clinically meaningful unbound drug concentration in gadolinium non-enhancing regions of the brain and inhibition of corresponding pharmacodynamic markers. Eight out of nine patients exceeded the pre-specified threshold for drug concentration in the brain tumor tissue and continued on study.
• Black Diamond anticipates the following upcoming key milestones for BDTX-1535:
  • Disclosure of initial Phase 2 data in 2L/3L EGFRm NSCLC patients with non-classical mutations or the acquired resistance C797S mutation remains on track for later in Q3 2024.
  • Disclosure of initial Phase 2 data in 1L EGFRm NSCLC patients with non-classical mutations remains on track for Q1 2025 (NCT05256290).
  • An abstract has been accepted for presentation at the 2024 European Society for Medical Oncology (ESMO) Congress titled “Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients with Non-classical EGFR Mutations Demonstrates High Unmet Medical Need”, which will detail an analysis of Guardant Inform data on treatment outcomes for newly diagnosed NSCLC patients with tumors expressing non-classical mutations.

BDTX-4933:

• BDTX-4933 is a brain-penetrant oral inhibitor of oncogenic alterations in KRAS, NRAS and BRAF.
• Enrollment of patients with BRAF and select RAS/MAPK mutation-positive cancers, with an emphasis on patients with KRAS mutant NSCLC, is progressing through escalating doses in a Phase 1 trial (NCT05786924). An update from this trial is on track for Q4 2024.

Corporate

• Chief Business Officer & Chief Financial Officer, Fang Ni, Pharm.D, will participate in a panel discussion at the Wedbush PacGrow Healthcare Conference taking place August 13-14, 2024, in New York, NY.

Financial Highlights

• Cash Position: Black Diamond ended the second quarter of 2024 with approximately $123.0 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023. Net cash used in operations was $14.7 million for the second quarter of 2024 compared to $14.4 million for the second quarter of 2023.
• Research and Development Expenses: Research and development (R&D) expenses were $12.6 million for the second quarter of 2024, compared to $13.2 million for the same period in 2023. The decrease in R&D expenses was primarily due to workforce efficiencies and reduced spending on early discovery projects.
• General and Administrative Expenses: General and administrative (G&A) expenses were $9.6 million for the second quarter of 2024, compared to $6.9 million for the same period in 2023. The increase in G&A expenses was primarily due to an increase in consulting and other professional fees.
• Net Loss: Net loss for the second quarter of 2024 was $19.9 million, as compared to $19.2 million for the same period in 2023.

Financial Guidance

• Black Diamond ended the second quarter of 2024 with approximately $123.0 million in cash, cash equivalents and investments which the Company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the fourth quarter of 2025.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the potential of BDTX-1535 to address the unmet medical need for newly diagnosed NSCLC patients with non-classical EGFR mutations and benefit patients with NSCLC across multiple lines of therapy, the continued development and advancement of BDTX-1535 and BDTX-4933, including the ongoing clinical trials and the timing of clinical updates for BDTX-1535 in patients with NSCLC and in patients with relapsed/recurrent GBM, and for Phase 1 clinical trial results for BDTX-4933, the expected timing for additional updates on data from the “window of opportunity” clinical trial of BDTX-1535 in patients with recurrent HGG, the potential future development plans for BDTX-1535 in NSCLC and GBM, the estimates regarding the market opportunities for the Company’s product candidates, and the Company’s expected cash runway. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission and in its subsequent filings filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Black Diamond Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (Unaudited) (in thousands)
	June 30, 2024				December 31, 2023
	(in thousands)
Cash, cash equivalents, and investments	$	122,971			$	131,400
Total assets	$	149,986			$	158,567
Accumulated deficit	$	(455,565	)		$	(417,431	)
Total stockholders’ equity	$	111,021			$	116,736

Black Diamond Therapeutics, Inc. Consolidated Statements of Operations (Unaudited) (in thousands, except per share data)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Operating expenses:
Research and development	$	12,556			$	13,154			$	26,101			$	27,907
General and administrative		9,574				6,878				16,275				13,686
Total operating expenses		22,130				20,032				42,376				41,593
Loss from operations		(22,130	)			(20,032	)			(42,376	)			(41,593	)
Other income (expense):
Interest income		464				539				1,101				1,161
Other income (expense)		1,757				341				3,141				405
Total other income (expense), net		2,221				880				4,242				1,566
Net loss	$	(19,909	)		$	(19,152	)		$	(38,134	)		$	(40,027	)
Net loss per share, basic and diluted	$	(0.36	)		$	(0.52	)		$	(0.71	)		$	(1.09	)
Weighted average common shares outstanding, basic and diluted		55,155,220				36,516,114				53,482,034				36,500,085

Contact

For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com

For Media:
media@bdtx.com

FAQ

What are the key upcoming milestones for BDTX-1535?

Black Diamond expects to disclose initial Phase 2 data in 2L/3L EGFRm NSCLC patients later in Q3 2024, and initial Phase 2 data in 1L EGFRm NSCLC patients with non-classical mutations in Q1 2025.

What is Black Diamond Therapeutics' cash position as of June 30, 2024?

Black Diamond reported a cash position of $123.0 million as of June 30, 2024, which is expected to fund operations into Q4 2025.

How did BDTX's R&D expenses change in Q2 2024 compared to Q2 2023?

R&D expenses decreased from $13.2 million in Q2 2023 to $12.6 million in Q2 2024, primarily due to workforce efficiencies and reduced spending on early discovery projects.

When does Black Diamond expect to share initial Phase 1 data of BDTX-4933?

Black Diamond anticipates sharing initial Phase 1 data of BDTX-4933 in KRASm NSCLC in Q4 2024.